Psychiatry & Neurology Doctors in Sedalia, MO Accepting Medicare

3 Psychiatry & Neurology doctors found. Showing 1 - 3

Asif Saeed Choudhary, M.D. Psychiatry & Neurology - Child & Adolescent Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 201 W 3rd St, Sedalia, MO 65301 Phone: 660-827-2494

Dr. David C Kuhlmann, M.D. Psychiatry & Neurology - Sleep Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 East 12th Street, Sedalia, MO 65301 Phone: 660-827-9573    Fax: 660-829-8865

Ms. Mary Ellen Beegle, D.O. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 119 East 4th Street, Sedalia, MO 65301 Phone: 660-553-5298    Fax: 660-553-5301

News Archive

McLean Researchers receive award to create first clinic-ready human induced iPS cells

Belmont, MA-Researchers at Harvard Affiliated McLean Hospital have been awarded a $1.9 million National Institutes of Health Director's Opportunity Award to continue their research into creating human induced pluripotent (iPS) stem cells using a method aimed at eliminating the risk of cancer and other problems associated with other options such as genome-integrating viral methods.

Home-based dialysis treatments appear to decline in developed countries

Home-based dialysis treatments are on the rise in both the developing and developed worlds, but developed countries appear to be turning to them less often, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

IU team develops statewide early ASD screening and evaluation system

A 2020 report from the Centers for Disease Control estimates that 1 in 54 children in the United States is identified each year with autism spectrum disorder.

Vascular Magnetics to advance development of new drug delivery system for PAD

Vascular Magnetics, the first start-up company spun off by The Children's Hospital of Philadelphia, has raised $7 million to advance development of an innovative drug delivery system using magnetically targeted nanoparticles to treat peripheral artery disease.

Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo. Additional clinical endpoints, including significant reduction in disability progression, as measured by Expanded Disability Severity Scale (EDSS), were also achieved.

Read more Medical News

› Verified 2 days ago